Literature DB >> 8071281

Concurrent use of clozapine and valproate in affective and psychotic disorders.

J C Kando1, M Tohen, J Castillo, F Centorrino.   

Abstract

BACKGROUND: This pharmaco-epidemiologic study was undertaken to determine if the combination of clozapine and valproate poses an increased risk of blood dyscrasias, liver function abnormalities, or other side effects and to develop dosing guidelines when the combination is utilized.
METHOD: The charts of 55 patients receiving clozapine and valproate concurrently between May 8, 1989, and May 8, 1992, were reviewed to determine the indication for and length of time on each medication, abnormalities in liver function test results, blood cell dyscrasias, seizures, nausea, vomiting, sedation, sialorrhea, and enuresis. In addition, the efficacy of the combination was measured.
RESULTS: The combination of clozapine and valproate was efficacious and well tolerated in the majority of patients. Major adverse effects such as blood dyscrasias or seizures were not experienced by the study population. The side effect that led to discontinuation of the combination most frequently was sedation.
CONCLUSION: The combination of clozapine and valproate is safe and efficacious.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8071281

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  10 in total

1.  Simultaneous side effects of both clozapine and valproate.

Authors:  J Nicolai; S J Smith; R W Keunen
Journal:  Intensive Care Med       Date:  2001-05       Impact factor: 17.440

2.  Adjunct divalproex or lithium to clozapine in treatment-resistant schizophrenia.

Authors:  Deanna L Kelly; Robert R Conley; Stephanie Feldman; Yang Yu; Robert P McMahon; Charles M Richardson
Journal:  Psychiatr Q       Date:  2006

3.  Re-titration rates after clozapine-induced neutropenia or agranulocytosis: A case report and literature review.

Authors:  Mina Boazak; Benjamin Kahn; Lindsay Cox; James Ragazino; David R Goldsmith; Robert O Cotes
Journal:  Clin Schizophr Relat Psychoses       Date:  2018-06-26

Review 4.  Augmentation strategies in clozapine-resistant schizophrenia.

Authors:  Gary Remington; Amitabha Saha; Siow-Ann Chong; Chekkera Shammi
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

Review 5.  Restarting clozapine after neutropenia: evaluating the possibilities and practicalities.

Authors:  Eromona Whiskey; David Taylor
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

Review 6.  Pharmacological augmentation strategies for schizophrenia patients with insufficient response to clozapine: a quantitative literature review.

Authors:  Iris E Sommer; Marieke J H Begemann; Anke Temmerman; Stefan Leucht
Journal:  Schizophr Bull       Date:  2011-03-21       Impact factor: 9.306

Review 7.  Seizure associated with clozapine: incidence, etiology, and management.

Authors:  Andrew M Williams; Susie H Park
Journal:  CNS Drugs       Date:  2015-02       Impact factor: 5.749

Review 8.  Interactions between antiepileptic and antipsychotic drugs.

Authors:  Frank M C Besag; David Berry
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

Review 9.  Clinically significant interactions of psychotropic agents with antipsychotic drugs.

Authors:  M C Meyer; R J Baldessarini; D C Goff; F Centorrino
Journal:  Drug Saf       Date:  1996-11       Impact factor: 5.606

10.  Clozapine-related EEG changes and seizures: dose and plasma-level relationships.

Authors:  Seema Varma; Delia Bishara; Frank M C Besag; David Taylor
Journal:  Ther Adv Psychopharmacol       Date:  2011-04
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.